APC News
FDA doubles down: Tirzepatide is off shortage
...but that doesn't mean the issue is completely settled.
December 20, 2024
Defending GLP-1 compounding
The latest letters APC's been sending to oppose efforts to restrict compounding
December 20, 2024
Thumbs-up for FDA crackdown
APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds.
December 20, 2024
A PANS/PANDAS explainer
For your patients: Information about a couple of underdiagnosed pediatric mental health conditions
December 20, 2024
What, a year?
In the final board chair column of the year, here are our top 7 accomplishments in 2024.
December 20, 2024
Earlier news
December 13, 2024
Get a cease and desist letter from Verrica?
APC has heard reports from several pharmacies that have received them — here's what to know.
December 12, 2024
PCF awards state association CE grants
The Pharmacy Compounding Foundation has awarded $1,500 grants to eight state pharmacy associations.
December 6, 2024
Compounding vs. counterfeit — ABC News gets it
When ABC News wanted to do a story on compounded GLP-1s, it turned to APC. Of course.
December 6, 2024
No no, Novo!
Novo Nordisk asked the FDA to put semaglutide on the Demonstrably Difficult to Compound (DDC) list, and now APC has formally responded, pulling exactly zero punches.
December 6, 2024
About that Diabetes Association statement …
The American Diabetes Association gets a good portion of its funding from pharmaceutical companies, including Eli Lilly and Novo Nordisk.
December 6, 2024
Foundation welcomes 2025 board members
Congratulations to the newest members of the Pharmacy Compounding Foundation Board of Directors
November 22, 2024
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages.
November 22, 2024
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.
November 22, 2024
NPR hits the GLP-1 nail on the head
A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right.
November 14, 2024
CALL TO ACTION: Tell FDA to deny drugmakers’ request
Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW!
November 8, 2024
APC to FDA: Just say no to Lilly
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list.
November 8, 2024
California BOP sends proposed compounding regs to comment period
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period.
